Co-Authors
This is a "connection" page, showing publications co-authored by SUSAN HILSENBECK and MEENAKSHI ANURAG.
Connection Strength
0.624
-
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations. Mol Cancer Ther. 2026 Jul 15.
Score: 0.246
-
Rat somatic genome editing enables ER+ breast cancer modeling. Proc Natl Acad Sci U S A. 2026 Jun 30; 123(26):e2529653123.
Score: 0.061
-
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2025 Nov 03; 15(11):2326-2343.
Score: 0.059
-
Rat somatic genome editing enables ER+ breast cancer modeling. bioRxiv. 2025 Sep 18.
Score: 0.058
-
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses. bioRxiv. 2025 Jan 08.
Score: 0.055
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 10 01; 23(10):1494-1510.
Score: 0.054
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
Score: 0.050
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
Score: 0.040